EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have improved clinical benefits for patients with metastatic non-small cell lung cancer (NSCLC) patients (Rosell et al., 2012).